Mercaptopurine (6MP) was approved by the Food and Drug Administration (FDA) for use in acute lymphoblastic leukemia in children and adults as part of combination therapy. However, there are several off-label uses for 6MP

- Maintenance treatment in childhood acute promyelocytic leukemia

- Non-Hodgkin lymphoma

- Lymphoblastic lymphoma

- Crohn disease management after surgical resection or as a steroid-sparing therapy

- Induction and remission maintenance in ulcerative colitis

- Rheumatoid arthritis

- Systemic lupus erythematosus (SLE)

- Psoriasis

- Childhood severe atopic eczema

- Treating autoimmune hepatitis in children

- Preventing tissue rejection after organ transplantation

- Other dermatological conditions